AMARILLO, Texas, July 15 /PRNewswire-FirstCall/ -- Amarillo Biosciences,
Inc. (OTC Bulletin Board: AMAR) announces the Company has signed a licensing
agreement with African Health Solutions, LLC, Greenville, Delaware providing
the rights to oral low-dose interferon alpha for the treatment of hepatitis B
patients in Africa.
Dr. Joseph M. Cummins, President and CEO of Amarillo Biosciences, Inc.
said, "Data from our human clinical trials and our mechanism of action studies
show that our low-dose oral interferon alpha is biologically active and well
tolerated. We are excited to partner with African Health Solutions to take
oral low-dose interferon alpha into Africa."
Jeffrey Busch, President of African Health Solutions said, "The
overwhelming health problems and the deteriorating economy of Africa dictate
that low cost, easy-to-administer, non-toxic therapies are needed. We have
studied alternative therapies and believe the interferon lozenges offer the
best opportunity to have an immediate impact on hepatitis B in Africa."
Hepatitis B is a chronic condition that affects approximately 10% of
Africans. Many HIV-positive individuals in Africa are concurrently infected
with hepatitis B virus, thereby greatly complicating treatment. Hepatitis B
is a severe, chronic, and debilitating condition treated with expensive drugs
financially out of reach for most Africans.
Hepatitis B is a chronic condition that affects approximately 10% of
Africans. Many HIV-positive individuals in Africa are concurrently infected
with hepatitis B virus, thereby greatly complicating treatment. Hepatitis B
is a severe, chronic, and debilitating condition treated with expensive drugs
financially out of reach for most Africans.
Amarillo Biosciences, Inc. also announces the expansion of their existing
relationship with Global Damon Pharm./Damon Pharm. Limited of Seoul, Korea.
Global Damon will be distributing Amarillo Biosciences, Inc.'s dietary
supplement for dry mouth in Korea.
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a pioneer in the research of low-dose orally
administered interferon alpha as a treatment for a variety of conditions
including Sjogren's syndrome, fibromyalgia syndrome, Behcet's disease,
hepatitis B and C, and opportunistic infections in patients who are HIV
positive. Additional information is available on the Amarillo Biosciences,
Inc. web site at http://www.amarbio.com .
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the Company's other product
candidates and other risks detailed from time to time in the Company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Description of Business" of the Company's Form 10-KSB for the year ended
December 31, 2001.
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amarbio.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html
CONTACT:
Dr. Joseph M. Cummins, President & CEO of
Amarillo Biosciences, Inc., +1-806-376-1741 ext. #13, or
jcummins@amarbio.com
|
